Kim Tae-Won

Description

I received my Ph.D. in Environmental and Molecular Toxicology from North Carolina State University in 1996, where my research focused on a skin carcinogenesis model. After completing my doctoral studies, I pursued a postdoctoral fellowship at the University of California, San Francisco, where I specialized in tumor metastasis and oral carcinogenesis.

Following this, I joined SUGEN as a toxicologist in the Department of Pharmacokinetics and Toxicology. I served as the Group Leader Toxicologist for the SUTEN project until 2001, and then transitioned to Ionis Pharmaceuticals.

Currently, I am the Vice President of Toxicology at Ionis Pharmaceuticals, where I lead the development of several approved therapies, including Mipomersen, Inotersen, Volanesorsen, Eplontersen, and Olezarsen. Additionally, I oversee projects under NDA review, such as Donidalorsen, along with multiple antisense oligonucleotide programs in various stages of development.